Shield TherapeuticsSTU:1JS Days Payable is 160.68 as of Dec. 2025, which is 70% below its 10-year median of 530.14. The stock has 5 warning signs investors should review. Among 923 Drug Manufacturers companies, Shield Therapeutics ranks better than 76.49% on this metric.
The historical rank and industry rank for Shield Therapeutics's Days Payable or its related term are showing as below:
STU:1JS'
s Days Payable Range Over the Past 10 Years
Min: 111.76 Med: 530.14 Max: 4975.92
Current: 157.24
During the past 12 years, Shield Therapeutics's highest Days Payable was 4975.92. The lowest was 111.76. And the median was 530.14.
STU:1JS's Days Payable is ranked better than 76.49% of 923
companies
in the Drug Manufacturers industry
Industry Median: 90.98
vs STU:1JS: 157.24
Shield Therapeutics's Days Payable
increased
from Dec. 2024 (112.49) to Dec. 2025 (160.68).
It may suggest that Shield Therapeuticsdelayed paying its suppliers.
Shield Therapeutics Days Payable Related Terms
Shield Therapeutics Days Payable Historical Data
* Premium members only.
The historical data trend for Shield Therapeutics's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:1JS vs ZTS, UTHR, VTRS: Days Payable Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Shield Therapeutics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shield Therapeutics Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Shield Therapeutics's Days Payable distribution charts can be found below:
* The bar in red indicates where Shield Therapeutics's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Shield Therapeutics's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shield Therapeutics (STU:1JS) has a Days Payable of 160.68 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Shield Therapeutics and its competitors. This is 70% below median its historical median of 530.14. Over the past decade, Shield Therapeutics' Days Payable has ranged from 111.76 to 4,975.92. According to the industry distribution chart, Shield Therapeutics ranks #217 out of 923 companies in the Drug Manufacturers industry, placing it in the top 23.5%.
Is Shield Therapeutics' Days Payable too high?
Shield Therapeutics' current Days Payable of 160.68 is 70% below median its 10-year median of 530.14. Over the past 10 years, this metric has ranged from a low of 111.76 to a high of 4,975.92. The Drug Manufacturers industry median Days Payable is 90.98. Shield Therapeutics' value of 160.68 is 76.6% above this industry median. Based on the distribution chart, Shield Therapeutics ranks #217 out of 923 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does Shield Therapeutics' Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Shield Therapeutics ranks #217 out of 923 companies for Days Payable. This places Shield Therapeutics in the top 24% of its industry — outperforming the majority of peers. The industry median Days Payable is 90.98. Shield Therapeutics' value of 160.68 is 76.6% above this benchmark. Historically, Shield Therapeutics' own Days Payable has ranged from 111.76 to 4,975.92 over the past decade. While the company's 10-year median is 530.14 vs. the industry median of 90.98, Shield Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.98, based on 923 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shield Therapeutics's current Days Payable of 160.68 is 76.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Shield Therapeutics and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shield Therapeutics's current Days Payable is 160.68, which is 70% below median its own 10-year median of 530.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shield Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Shield Therapeutics (STU:1JS) is currently considered Modestly Undervalued. The stock's GF Value™ is €0.09, compared to a current price of €0.07 — trading 24.4% below its estimated fair value. The current Days Payable is 160.68, which is 70% below median its 10-year median of 530.14 and 76.6% above the Drug Manufacturers industry median of 90.98. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Shield Therapeutics (STU:1JS), the current Days Payable is 160.68 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Shield Therapeutics PLC is a commercial-stage specialty pharmaceutical company that delivers ACCRUFeR/FeRACCRU (ferric maltol), a differentiated pharmaceutical product, to address the unmet need for patients suffering from iron deficiency, with or without anemia. The company has launched ACCRUFeR in the U.S. Outside of the U.S., it has licensed the rights to specialty pharmaceutical companies. FeRACCRU is commercialised in the UK, the European Union, and Canada, with marketing rights in Australia and New Zealand. The company's operating segments are: FeRACCRU, which generates the maximum revenue, and PT20. Geographically, it generates maximum revenue from the U.S., and the rest from the Netherlands, Canada, Japan, and South Korea.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:1JS has been successfully added to your 